Among breast cancer survivors who became pregnant, 34% resumed endocrine therapy (ET) by 2 years postdelivery, with a 19% cumulative incidence of subsequent breast cancer events at 10 years. The ...

SAN ANTONIO -- Endocrine therapy after breast-conserving surgery was associated with worse health-related quality of life (HRQOL) compared with radiotherapy in older women with luminal A-like early ...

Recommendation based on DESTINY-Breast06 phase 3 trial results which showed ENHERTU demonstrated superiority versus chemotherapy with a median progression-free survival of more than one year TOKYO & ...

Based on DESTINY-Breast06 phase 3 trial results which showed ENHERTU demonstrated superiority versus chemotherapy with a median progression-free survival of more than one year Approval brings Daiichi ...

Immunohistochemistry (IHC) is a newer technique for assessing the estrogen receptor (ER) status of breast cancers, with the potential to overcome many of the shortcomings associated with the ...

The mean change from baseline in the mean daily frequency of moderate-to-severe vasomotor symptoms at week 4 was −6.5 and −3.0 episodes for those receiving elinzanetant and placebo, respectively.

A groundbreaking international study has found that imlunestrant plus abemaciclib significantly improved progression-free survival (PFS) versus imlunestrant monotherapy in patients with estrogen ...

The Breast Cancer Index (BCI) may help identify patients with low-risk breast cancer who could potentially benefit from reduced endocrine therapy, leading to improved quality of life and potentially ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Most women with breast cancer who paused endocrine ...

For many women, surviving breast cancer feels like reaching the finish line, but sometimes can be the start of a new set of health challenges. One major concern? A higher cardiovascular disease (CDV) ...

HERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer Previously Treated with Endocrine Therapy The ...

Recognized for Advancing (Z)-Endoxifen, a Precision-Engineered Endocrine Therapy with Potential Across Multiple Breast Cancer and Rare Disease Settings Atossa earned this recognition for its ...